文献速递瓣膜外科

机器人辅助冷冻Cox迷宫术治疗持续性心房颤动的纵向随访

Robotic-assisted cryothermic Cox maze for persistent atrial fibrillation: Longitudinal follow-up.
PubMed 文献 · J Thorac Cardiovasc Surg · 2022-05-18

本研究报告了2016年11月至2022年1月连续接受机器人双心房冷冻Cox迷宫术的非阵发性心房颤动患者的纵向随访结果。共135例患者,平均随访17±14.5个月,无房性快速性心律失常且无需抗心律失常药物的成功率在9、12、18、24、36、48个月分别为97.0%、96.7%、98.1%、97.1%、100%。作者结论认为该术式可为持续性心房颤动提供1年纵向无卒中、无口服抗凝、无重复消融及无复发的获益,且无需抗心律失常药物。

要点

  • 机器人双心房冷冻Cox迷宫术治疗持续性心房颤动,1年纵向无房性快速性心律失常且无需抗心律失常药物成功率超过90%。
  • 135例患者中,25.2%接受孤立迷宫术,61.4%同期行机器人二尖瓣手术,7.4%行三尖瓣修复,4.4%行主动脉瓣置换。
  • 手术死亡3例(2.2%),孤立迷宫术患者无手术死亡。

核心结论

  • 对于持续性心房颤动,机器人双心房冷冻Cox迷宫术提供了超过90%的1年纵向无卒中、无口服抗凝、无重复消融及无复发性心房颤动的成功率,且无需抗心律失常药物。

研究设计与样本

  • 单中心连续病例系列,纳入2016年11月至2022年1月接受机器人双心房冷冻Cox迷宫术的非阵发性心房颤动患者,共135例。
  • 随访时间点为术后1、2、3、6、9、12、18、24、36、48和60个月;6个月后所有患者通过24小时连续心电图或起搏器 interrogation 评估无房性快速性心律失常。
  • 平均随访17±14.5个月(范围1-60个月)。
  • 采用竞争风险的时间至事件分析确定与晚期结局的风险校正关联。

主要发现

  • 患者中位心房颤动持续时间为4.0年(四分位距0.8-7.0),29.6%的患者有1次或以上导管消融失败。
  • 孤立迷宫术占25.2%,同期机器人二尖瓣手术占61.4%,三尖瓣修复占7.4%,主动脉瓣置换占4.4%。
  • 无患者出院时处于心房颤动状态。
  • 手术死亡3例(2.2%),孤立迷宫术患者中无手术死亡。
  • 1例患者术后8个月需要导管消融,1例术后18个月发生非栓塞性卒中;晚期死亡9例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Surgical ablation of atrial fibrillation (AF) is recommended as a stand-alone therapy for patients refractory to medical or catheter-based treatment, or as a concomitant therapy when associated with structural disease. We report a single-therapy robotic approach to the Cox maze with longitudinal follow-up. METHODS: Consecutive patients who underwent robotic biatrial cryothermic Cox maze for nonparoxysmal AF between November 2016 and January 2022 were examined at 1, 2, 3, 6, 9, 12, 18, 24, 36, 48, and 60 months. Freedom from atrial tachyarrhythmia was assessed with 24-hour continuous electrocardiogram or pacemaker interrogation in all patients after 6 months. Mean follow-up was 17 ± 14.5 months (range, 1-60 months). Time to event analysis with competing risks was used to determine risk-adjusted associations with late outcomes. RESULTS: Patients (n = 135) had a median AF duration of 4.0 years (interquartile range, 0.8-7.0), with 29.6% in whom 1 or more catheter ablations had failed. Stand-alone maze was performed in 25.2%, whereas 61.4% underwent concomitant robotic mitral valve surgery, 7.4% tricuspid valve repair, and 4.4% aortic valve replacement. No patients were discharged in AF. There were 3 operative mortalities (2.2%), none in stand-alone patients. One patient required catheter ablation at 8 months postoperatively, and one had a nonembolic stroke at 18 months. There were 9 late deaths. Freedom from atrial tachyarrhythmia and antiarrhythmic drugs at 9, 12, 18, 24, 36, and 48 months was 97.0%, 96.7%, 98.1%, 97.1%, and 100%, respectively. Lower ejection fraction and need for concomitant mitral valve replacement and/or aortic valve replacement were independently associated with worse survival. CONCLUSIONS: For persistent AF, robotic biatrial cryothermic Cox maze offered greater than 90% 1-year longitudinal freedom from stroke, oral anticoagulation, repeat ablation, and recurrent AF without the need for antiarrhythmic drugs.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Almousa A, Mehaffey JH, Wei LM, et al. Robotic-assisted cryothermic Cox maze for persistent atrial fibrillation: Longitudinal follow-up. J Thorac Cardiovasc Surg. 2022. PMID: 36028363. doi:10.1016/j.jtcvs.2022.05.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。